Apyx One console approved for commercial launch in South Korea. Initial orders expected to start shipping in Q4 2025. South Korea's cosmetic surgery market projected to grow from $1.7B to $3.9B. Renuvion technology targets post-weight-loss skin solutions for patients. Seoul recognized as a global leader in cosmetic surgery and medical tourism.
The approval and launch in South Korea signify growth potential. Historical examples suggest foreign expansions can boost company valuations.
Long-term growth expected as market expands to accommodate advanced cosmetic technologies and increasing demand.
The South Korean market is lucrative, indicating that success can significantly influence APYX's price.